BioMerieux, ExonHit to Develop Dx to Help Predict Surgery Risk in Prostate Cancer

Jan 05, 2007

NEW YORK (GenomeWeb News) — BioMérieux and ExonHit Therapeutics plan to develop a blood-based prostate-cancer screening test aimed at helping doctors weigh the risks of performing surgery to remove tumors, BioMérieux said yesterday.

Under the collaboration, BioMérieux will use ExonHit’s genome expression IP to develop DNA chips that can detect “several dozens of nucleic acid markers” and use them to find cancer markers in blood.

Financial terms of the agreement were not released.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

In on the Action

NPR reports that with medical data being big business, some companies want to get patients involved.

What's in Store?

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

This Week in PNAS

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Warren Releases Genetic Ancestry Results

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Featured White Papers

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Probe Design and In Vitro Validation Quick Start Guide

Oct

25

Featured Webinar

A Comprehensive Strategy for Evaluating NGS Liquid Biopsy and Tumor Tissue Assays

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.

Main menu